Avita Medical Announces Issuance of a New U.S. Patent for ReCell
“This newly issued patent continues to strengthen and expand our overall patent coverage for ReCell. Moving forward, we are continuing to focus on the prosecution of additional patents that support our entire regenerative medicine franchise. This patent is a key milestone towards our commercialisation effort in the US” commented Adam Kelliher, CEO of Avita Medical.
The patent provides protection for methods for producing and using a transplantable cellular suspension of living tissue suitable for grafting to a patient. Avita has a robust intellectual property portfolio for its regenerative technology platform. ReCell®, ReGenerCell™ and ReNovaCell™ are protected by a family of patents and patent applications covering unique composition of final product, method of production, device and automation for methods and apparatus to generate epithelial suspension. Currently, pending worldwide patents and applications will expire in 2022-2034. Additional filings having a later expiration date will be made as Avita continues to invent in the regenerative medicine field.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.